Fears Nachawati Attorneys At Law

Nationwide actos Law Firm
YOU HAVE BLADDER CANCER? WERE YOU TAKING ACTOS TO CONTROL TYPE 2 DIABETES?
According to the FDA, the use of Actos can lead to a 40% increased risk of Bladder Cancer.
This information is based on a 10-year study of more than 200,000 patients with type 2 diabetes.

Actos, which was first approved in 1999 to lower blood sugar in people with type 2 diabetes, has now been banned in France and Germany. No such action has been taken as yet in the US.

FDA ORDERS BLACK BOX WARNING



The FDA ordered Actos manufacturer Takeda Pharmaceuticals to issue a black box warning (the strongest FDA-requested label change) about the serious risk of heart attack, heart failure and cardiovascular-related deaths.

FDA ISSUES SAFETY ALERT



The FDA released a safety alert on Actos about the 40% increased risk of bladder cancer in people taking high doses of Actos or who take it for more than a year. In August 2011, the FDA ordered a label change reflecting this information.

Actos Maker to Pay $9 Billion in Damages


A federal court jury found Takeda, the maker of Actos, hid the cancer risks associated with the diabetes drug and was ordered to pay $9 billion in punitive damages.

SEVERE SIDE EFFECTS CAUSED BY ACTOS INCLUDE

  • Bladder Cancer
  • Heart Failure
  • Macular Edema
  • Bone Fractures
  • Liver Failure
  • Hypoglycemia (when taken with Insulin)
we can help
Drug manufacturers have the responsibility to adequately warn patients about risks associated with taking medications. When Big Pharmaceutical Companies fail to provide warnings, our law firm's job is to hold them accountable.

Our lawyers have recovered millions of dollars for families to help cover medical costs and provide care to loved ones injured by Pharmaceutical Companies that put profits over the safety of patients.

Fill out our law firm's form or call today while there is still time to submit a claim and hold companies responsible for placing lives in danger.
DON'T MISS YOUR 
TIME LIMIT FOR MAKING A CLAIM